• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Potential therapeutic roles for antibody mixtures
【24h】

Potential therapeutic roles for antibody mixtures

机译：抗体混合物的潜在治疗作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

With the enormous success of recombinant monoclonal antibodies (rMAbs) as human therapeutics, there are increasing efforts underway to explore new molecular entities that mimic rMAbs to replicate this huge success. In addition to naked intact rMAbs, antibody drug conjugates (ADCs), FAb and F(ab′)2 fragments and also Fc fusion proteins have been developed and/or marketed as human therapeutics to treat different human diseases, including life-threatening diseases such as cancer. Several hundreds more intact rMAbs, ADCs, FAb, F(ab′)2 fragments and Fc fusion proteins are currently undergoing human clinical trials. In addition to these molecules, new type of antibody fragments such as single-chain Fvs (scFvs), VH, scFv-Fc, scFv-CH, scFAb, scFv-zipper, diabodies, bispecific antibodies and similar types of constructs are also being investigated to be developed as human monotherapeutics. Further, there are quite a few current examples of combinations of biologics being developed. For example, currently, several biopharmaceutical companies are developing combinations of antibody mixtures as human therapeutics. Accordingly, the question posed here is whether it is time to consider the possibility of developing a broader range of combinations of therapeutic biologics. Combinations of small organic molecules have been successfully used as therapeutics for many years to treat many diseases, so the context of using polypharmacology to treat human diseases is not novel. For the past several decades, intravenous immunoglobulins have successfully been used in treating various autoimmune diseases. In this context, several biotechnology companies are exploring the use of combinations of antibody mixtures as human therapeutics. This editorial discusses these current efforts and the potential future role of antibody mixtures as human therapeutics.
机译：随着重组单克隆抗体（rMAb）作为人类治疗剂的巨大成功，人们正在加大力度探索模仿rMAb的新分子实体以复制这一巨大成功。除裸露的完整rMAb外，抗体药物偶联物（ADC），FAb和F（ab'）2片段以及Fc融合蛋白也已开发和/或销售为治疗各种人类疾病（包括危及生命的疾病）的人类疗法作为癌症。目前，数百种完整的rMAb，ADC，FAb，F（ab'）2片段和Fc融合蛋白正在接受人体临床试验。除了这些分子之外，还在研究新型抗体片段，例如单链Fv（scFvs），VH，scFv-Fc，scFv-CH，scFAb，scFv拉链，双抗体，双特异性抗体和类似类型的构建体被发展为人类单一疗法。此外，目前有许多正在开发的生物制剂组合的例子。例如，当前，一些生物制药公司正在开发抗体混合物的组合作为人类治疗剂。因此，这里提出的问题是，是否该考虑开发治疗生物制剂的更广泛组合的可能性了。多年以来，有机小分子的组合已成功地用作治疗多种疾病的疗法，因此使用多药理学治疗人类疾病的背景并不新颖。在过去的几十年中，静脉内免疫球蛋白已成功用于治疗各种自身免疫性疾病。在这种情况下，一些生物技术公司正在探索将抗体混合物的组合用作人类治疗剂的用途。这篇社论讨论了这些当前的努力以及抗体混合物作为人类治疗剂的潜在未来作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号